These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 33352494)

  • 1. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.
    Ganesan K; Xu C; Wu J; Du B; Liu Q; Sui Y; Song C; Zhang J; Tang H; Chen J
    Sci China Life Sci; 2024 Sep; 67(9):1849-1866. PubMed ID: 38900236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Robles AJ; Cai S; Cichewicz RH; Mooberry SL
    Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
    Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
    Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
    Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
    Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effecacy of Biejia (Carapax Trionycis) and Ezhu (Rhizoma Curcumae Phaeocaulis) couplet medicine on epithelial-mesenchymal transition, invasion and migration of MDA-MB-231 triple negative breast cancer cells via PI3K/Akt/mTOR signaling pathway.
    Zhu MJ; Xie S; Xie Q; Zhu JL; Huang YZ
    J Tradit Chin Med; 2021 Dec; 41(6):853-861. PubMed ID: 34939381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
    J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma.
    Yang Z; Liu H; Song Y; Gao N; Gao P; Hui Y; Li Y; Fan T
    Int J Mol Med; 2024 Sep; 54(3):. PubMed ID: 38994756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
    Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
    Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial-Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells.
    Chou CH; Wang HK; Lin YC; Tsai DH; Lu MT; Ho CT; Hseu YC; Yang HL; Way TD
    J Agric Food Chem; 2021 Dec; 69(48):14557-14567. PubMed ID: 34813306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
    Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
    Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin suppresses metastasis of triple-negative breast cancer cells by modulating EMT signaling pathways: An integrated study of bioinformatics analysis.
    Chen Z; Lu P; Li M; Zhang Q; He T; Gan L
    Medicine (Baltimore); 2024 Feb; 103(8):e37264. PubMed ID: 38394486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.
    Yang B; Huang J; Xiang T; Yin X; Luo X; Huang J; Luo F; Li H; Li H; Ren G
    J Appl Toxicol; 2014 Jan; 34(1):105-12. PubMed ID: 24122885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.